Kuick Research Recent Publication Includes Top 330 Domestic Pharmaceutical Companies In China

Delhi, Sept. 01, 2023 (GLOBE NEWSWIRE) — China Pharmaceutical Companies Database & Drugs Pipeline Insight 2023 Highlights:

• All Companies Are Domestic Chinese Companies
• Chinese Pharmaceuticals Companies Business Overview Insight: 330 Companies
• Comprehensive Insight On Drugs In Clinical Trials By Companies: > 1500 Drugs
• Clinical Trials Insight By Companies, Indication, Formulation & Phase
• Comprehensive Insight On Drugs Commercially Approved In Market: > 200 Drugs
• Biosimilar, Branded & Generics Drugs Classification

Download Sample: https://www.kuickresearch.com/ccformF.php?t=1693561853

The well established pharmaceutical industries of the US and EU are now facing stiff competition from China’s rapidly growing pharmaceutical industry. This change is being driven by a number of critical factors. A growing middle class and China’s massive market have resulted in an increase in domestic demand for pharmaceutical products, establishing a foundation for the sector’s growth. Chinese pharmaceutical companies have made substantial expenditures in innovation and research and development. Companies such as Jiangsu Hengrui Medicine and Hutchison China MediTech (Chi-Med) have made major strides in developing advanced drugs, particularly in oncology. Akeso’s innovative oncology drugs, like Cadonilimab, are well-known internationally.

Furthermore, by enhancing its regulatory environment, China has expedited the drug development and approval processes. As a result, Chinese and foreign pharmaceutical companies are currently conducting research and development there. China’s active participation in international alliances has facilitated international collaborations and expansion, demonstrating the country’s company’s drive to compete on a global scale. As a result of these advancements, the Chinese pharmaceutical companies is ready to shake up the competitive environment globally and threaten the pharmaceutical industries’ dominance of the US and EU.

We have compiled a comprehensive list that includes every active player in China’s pharmaceutical market. The database contains critical information about these companies, such as their ongoing clinical and preclinical trial candidates, and provides an encompassing perspective of their research focus. Furthermore, the database highlights these companies’ strategic license deals, putting light on their cooperation endeavors. Aside from that, the database looks into the patented technology platforms used by these companies, providing insights into the cutting-edge processes and tools that push their research and development efforts. To summarize, this unique resource not only presents a vivid image of China’s pharmaceutical landscape, but it also acts as a vital navigator for investors, stakeholders, and scholars created to help them sail through the complex world of the Chinese pharmaceutical industry.

Neeraj Chawla
Kuick research
Research Head
[email protected]
https://www.kuickresearch.com